AZD2171
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastrointestinal Stromal Tumors
Conditions
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
Trial Timeline
Sep 1, 2006 → Dec 1, 2009
NCT ID
NCT00385203About AZD2171
AZD2171 is a phase 2 stage product being developed by AstraZeneca for Gastrointestinal Stromal Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00385203. Target conditions include Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas.
What happened to similar drugs?
6 of 20 similar drugs in Gastrointestinal Stromal Tumors were approved
Approved (6) Terminated (4) Active (10)
🔄Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00621725 | Phase 1 | Completed |
| NCT00385203 | Phase 2 | Completed |
| NCT00243347 | Phase 1 | Completed |
| NCT00503412 | Phase 1 | Completed |
| NCT00264004 | Phase 2 | Completed |
| NCT00503477 | Phase 1 | Completed |
| NCT00502385 | Phase 1 | Completed |
| NCT00502164 | Phase 1 | Completed |
| NCT00501605 | Phase 1 | Completed |
Competing Products
20 competing products in Gastrointestinal Stromal Tumors